Codeine

Generic Name: Codeine

Brand Names: Ascomp, Cheratussin, Cheratussin Dac, Codar Ar, Codar D, Codar Gf, Codeine Contin, Covan, Damylin With Codeine, Fioricet With Codeine, Histex Ac, Linctus Codeine Blanc, M-clear Wc, M-end PE, Mar-cof BP, Mar-cof Cg, Mersyndol, Ninjacof Xg, Pseudodine C, Robaxacet-8, Robaxisal, Triacin-C, Trianal C, Triatec, Triatec-30, Triatec-8, Tusnel C, Tuxarin, Tuzistra, Tylenol With Codeine

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁NO_₃

CAS Number: 76-57-3

Unique Ingredient Identifier: UX6OWY2V7J

Background: The relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. Codeine, an opioid analgesic, was originally approved in the US in 1950 and is a drug used to decrease pain by increasing the threshold for pain without impairing consciousness or altering other sensory functions. Opiates such as codeine are derived from the poppy plant, Papaver somniferum (Papaveraceae).

Codeine is utilized as a central analgesic, sedative, hypnotic, antinociceptive, and antiperistaltic agent, and is also recommended in certain diseases with incessant coughing.

Indication: Codeine sulfate is a form of this drug that is commonly used. It is available in tablet form and indicated for the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate .

The solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above , .

Associated Conditions: Common Cold, Cough, Flu caused by Influenza, Mild pain, Pain, Severe Pain, Dry cough, Moderate Pain, Upper respiratory symptoms

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study

Phase 1

Completed

Conditions: Cough

Interventions: Drug: Codeine Phosphate/Guaifenesin IR Tablet
Drug: Codeine Phosphate/Guaifenesin ER Tablet

First Posted Date: 2015-10-08

Last Posted Date: 2017-03-29

Lead Sponsor: Nexgen Pharma, Inc

Target Recruit Count: 38

Registration Number: NCT02572375

Locations: 🇯🇴
Pharmaceutical Research Unit, Amman, Jordan

Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction.

Phase 4

Completed

Conditions: Impacted Third Molar Tooth

Interventions: Drug: Codeine + Diclofenac
Drug: Diclofenac

First Posted Date: 2015-09-11

Last Posted Date: 2015-09-11

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 50

Registration Number: NCT02547896

A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.

Not Applicable

Completed

Conditions: Headache

Interventions: Drug: Codeine
Drug: Metoclopramide
Drug: Diphenhydramine

First Posted Date: 2014-11-20

Last Posted Date: 2018-04-02

Lead Sponsor: St. Louis University

Target Recruit Count: 70

Registration Number: NCT02295280

Locations: 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States

Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics

Phase 1

Completed

Conditions: Drug Biotransformation
Membrane Transport

Interventions: Drug: Codeine
Drug: Midazolam
Drug: Pravastatin
Drug: Torsemide
Drug: Talinolol
Drug: Caffeine
Drug: Metoprolol

First Posted Date: 2013-05-03

Last Posted Date: 2014-04-21

Lead Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Target Recruit Count: 117

Registration Number: NCT01845194

Locations: 🇩🇪
Dept. of Clinical Pharmacology, Georg-August-University of Goettingen, Goettingen, Germany

Open Label Study for the Functional Characterization of Drug Metabolism and Transport

Phase 1

Completed

Conditions: Genotype-related Drug Metabolism

Interventions: Drug: Codeine
Drug: Midazolam
Drug: pravastatin
Drug: Talinolol
Drug: torsemide

First Posted Date: 2013-02-11

Last Posted Date: 2015-05-27

Lead Sponsor: Matthias Schwab

Target Recruit Count: 144

Registration Number: NCT01788254

Locations: 🇩🇪
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
🇩🇪
Abteilung Klinische Pharmakologie, Tübingen, Germany